Apeloa Pharmaceutical Co. Ltd. Class A

As of June 30, 2026, Apeloa Pharmaceutical Co. Ltd. Class A carries a market capitalization of 19.30B, placing it among publicly traded companies globally. Its enterprise value stands at 17.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Apeloa Pharmaceutical Co. Ltd. Class A's next confirmed earnings release is scheduled for March 5, 2027.

As of June 30, 2026, Apeloa Pharmaceutical Co. Ltd. Class A has 1.16B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Apeloa Pharmaceutical Co. Ltd. Class A maintains a current ratio of 1.58, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Apeloa Pharmaceutical Co. Ltd. Class A recorded 135.62M in income tax expense.

As of the close on October 23, 2026, Apeloa Pharmaceutical Co. Ltd. Class A's stock has gained approximately 29.30% over the past 52 weeks. The 50-day moving average sits at 22.88, while the 200-day moving average is 19.10.

As of June 30, 2026, Apeloa Pharmaceutical Co. Ltd. Class A holds 3.06B in cash and equivalents against 1.53B in total debt, resulting in a net debt position of -1.55B. Total book value stands at 6.57B, with working capital of 2.87B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Apeloa Pharmaceutical Co. Ltd. Class A paid dividends of 0.25 per share.

Apeloa Pharmaceutical Co. Ltd. Class A's most recent stock split took place on May 30, 2014 with a 10:13 split ratio.